logo

[breadcrumb_custom]

Arbutus Biopharma Corp (ABUS) Stock: From Low to High in 52 Weeks

The 52-week high and low prices can offer valuable insights into a stock’s current standing and prospects for future performance. Arbutus Biopharma Corp’s current trading price is -7.38% away from its 52-week high, while its distance from the 52-week low is 70.99%. The stock’s price range for this period has been between $1.69 and $3.12 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 1.98 million for the day, a number notably higher than the average daily volume of 0.94 million over the last three months.

The market performance of Arbutus Biopharma Corp’s stock has been turbulent in recent times. Over the last year, the company’s stock reached its highest point at $3.12 on 04/04/23, while the lowest value for the same duration was $1.69 on 10/24/23.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis

Arbutus Biopharma Corp (ABUS) has experienced a quarterly rise of 11.58% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 518.69M and boasts a workforce of 73 employees.

Analyzing Trading Volume and Moving Average Trends

Based on Barchart.com data, the company’s moving average over the 100-day period was 2.39, with a change in price of +0.69. Similarly, Arbutus Biopharma Corp recorded 874,419 in trading volume during the last 100 days, posting a change of +37.24%.

Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis

The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for ABUS stands at 0.08. Similarly, the long-term debt-to-equity ratio is also 0.08.

ABUS Stock Stochastic Average

As of today, Arbutus Biopharma Corp’s raw stochastic average for the last 50 days stands at 39.42%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 31.73%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 31.91% and 35.57%, respectively.

ABUS Stock Price Performance Analysis

A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. Year to date metric has recorded a gain of 15.59%.However, over the last six months, we can see a weaker performance of 50.51%. Over the last 30 days, the price of ABUS has fallen by 6.63%. And in the last five days, it has surged by 16.06%.

On Key

Related Posts